U.S. markets close in 1 hour 36 minutes
  • S&P 500

    3,838.42
    -31.87 (-0.82%)
     
  • Dow 30

    31,427.36
    +35.84 (+0.11%)
     
  • Nasdaq

    13,043.29
    -315.49 (-2.36%)
     
  • Russell 2000

    2,220.79
    -10.72 (-0.48%)
     
  • Crude Oil

    61.30
    +1.55 (+2.59%)
     
  • Gold

    1,715.70
    -17.90 (-1.03%)
     
  • Silver

    26.31
    -0.57 (-2.12%)
     
  • EUR/USD

    1.2073
    -0.0015 (-0.12%)
     
  • 10-Yr Bond

    1.4670
    +0.0520 (+3.67%)
     
  • GBP/USD

    1.3957
    +0.0001 (+0.00%)
     
  • USD/JPY

    106.9890
    +0.2790 (+0.26%)
     
  • BTC-USD

    50,480.15
    +2,689.98 (+5.63%)
     
  • CMC Crypto 200

    1,011.20
    +23.10 (+2.34%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Nikkei 225

    29,559.10
    +150.93 (+0.51%)
     

Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day

  • Oops!
    Something went wrong.
    Please try again later.
Arvinas Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW HAVEN, Conn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks: 2021 Oncology Day on Thursday, February 11 at 4:30 p.m. ET.

A live audio webcast of the presentation will be available here and on Arvinas’ website at www.arvinas.com. A replay of the webcast will be archived on Arvinas’ website for 30 days following the presentation.

About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.

Contacts for Arvinas

Investors
Will O’Connor, Stern Investor Relations
ir@arvinas.com

Media
Kirsten Owens, Arvinas Communications
kirsten.owens@arvinas.com